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Abstract
Dobutamine stress testing is an important non-invasive method for evaluating patients with
known or suspected coronary artery disease who are unable to adequately exercise. We present
a case of a paradoxical, progressive bradycardia occurring with increasing doses of dobutamine
that resulted in stress test interruption. (Cardiol J 2012; 19, 1: 79–80)
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Pharmacological stress testing is an important
non-invasive method for evaluating patients with
known or suspected coronary artery disease who
are unable to adequately exercise [1]. In combina-
tion with echocardiography, pharmacological stres-
sors such as dobutamine and dipyridamole are used
[1]. The safety of the stress test is a major determi-
nant in the choice of the agent [1]. With dobutamine
stress testing, side effects such as ventricular tachy-
cardia, torsade de pointes, fatal ventricular fibrilla-
tion, cardiogenic shock, free wall rupture or tran-
sient ischemic attack have all been reported [2].
We present a case of an unusual chronotropic
response to increasing doses of dobutamine that oc-
curred on stress echocardiography, i.e. progressive
bradycardia leading to test interruption.
A 44 year-old man was referred to our depart-
ment due to suspected in-stent restenosis six
months after acute myocardial infarction that was
treated with stent-assisted primary angioplasty
of the left anterior descending artery. The patient
was sent to our echo lab for the assessment of left
ventricular contractility on dobutamine stress echo.
The baseline echocardiogram revealed apical
akinesis and hypokinesis of the anterior wall, with
an overall ejection fraction of 50%. The baseline
heart rate (HR) was 63 bpm, blood pressure (BP)
was 115/70 mm Hg. The beta-adrenolytic agent
(bisoprolol 5 mg) was stopped on the day before the
test. Dobutamine was infused at a dose commenc-
ing at 5 mg/kg/min and increasing incrementally by
5 mg/kg/min every three minutes. The values of HR
and BP during the test are shown in Table 1.
During the test, in spite of a normal BP re-
sponse and a lack of chest pain, the patient com-
plained of progressive weakness, which made us
interrupt the test at 13 min. Electrocardiography
(ECG) revealed a progressive sinus bradycardia
(Table 1) while no atrioventricular conduction block
was observed. No new wall motion abnormalities
Table 1. Parameters during dobutamine stress.
Time Dosage Heart Blood
[mg/kg/min] rate  pressure
 [bpm]  [mm Hg]
Baseline – 63 115/70
3 min 5 63 115/70
6 min 10 57 140/75
9 min 15 47 160/80
12 min 20 45 170/80
80
Cardiology Journal 2012, Vol. 19, No. 1
www.cardiologyjournal.org
were observed. Several minutes after the test in-
terruption, the symptoms of weakness resolved,
and HR and BP returned to baseline. Coronary an-
giography was performed on the following day. It
revealed a widely patent stent and no progression
of atherosclerosis.
Isolated, progressive sinus rhythm decelera-
tion during dobutamine stress echocardiography has
not been thus far reported in humans. However,
dobutamine-induced bradycardia has been report-
ed in dogs and horses [3, 4] although its mechanism
was unclear. In humans, a paradoxical sudden sinus
deceleration has been reported only with peak do-
butamine doses (i.e., a sudden rather than a pro-
gressive effect) and it has always been accompanied
by arterial hypotension. In a series of 58 patients
subjected to dobutamine perfusion scintigraphy,
Hopfenspringer et al. [5] reported such an effect in
17% of cases; this was seen usually in patients with
an inferior wall perfusion defect. The exact mecha-
nism responsible for a sudden bradycardia during
dobutamine stress echo is unclear. A sudden sinus
rhythm deceleration may be the result of Bezold-
-Jarisch reflex, an intracardiac parasympathetic ner-
vous reflex responsible for bradycardia, hypoten-
sion and vasodilatation. The Bezold-Jarisch reflex
may be stimulated by vigorous myocardial contrac-
tions occurring when ventricular filling is reduced,
as may occur during dobutamine infusion [6].
In contrast to prior reports, the sinus brady-
cardia in our patient was progressive and it occurred
in spite of a normal BP response (Table 1). It oc-
curred 6 min after the beginning of dobutamine in-
fusion (dobutanime dose 10 mg/kg/min). In contrast
to previous reports, the bradycardia was accompa-
nied by an increase in BP (max. 170/80 mm Hg).
Such an effect is unlikely to be caused by the
Bezold-Jarisch reflex. Similarly, it is unlikely to be
caused by the baroreflex response, as the BP in-
crease was mild (Table 1).
In this patient, the right and circumflex coro-
nary arteries were free of atherosclerosis and the
stent in the left anterior descending artery was
widely patent.
Six months after the test, the patient was free
of symptoms, and physical examination and 24 hour
ECG monitoring were normal.
We report that a paradoxical, progressive
bradycardia can occur with increasing doses of dobu-
tamine and it may bring about stress test interrup-
tion. Such a paradoxical effect, accompanied by
a normal BP response, has not been reported pre-
viously. Physicians performing stress echo should
be aware of such a side effect.
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